

Fund Details

Investment Objective

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved.

Fund Manager

Mr. Dhaval Shah & Mr. Dhaval Joshi

Date of Allotment

July 11, 2019

Benchmark

BSE Healthcare TRI

Managing Fund Since

July 11, 2019 & November 21, 2022

Experience in Managing the Fund

5.0 Years & 1.6 Years

SIP

Daily/Weekly/Monthly: Minimum ₹ 100/-

Fund Category

Thematic (Equity)

Investment Style

Large Cap			
Mid Cap			
Small Cap			
	Growth	Value	Blend



Load Structure (as % of NAV) (Incl. for SIP)

Entry Load	Nil
Exit Load	For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil

AUM

Monthly Average AUM	₹	704.78	Crores
AUM as on last day	₹	713.42	Crores

Total Expense Ratio (TER)

Regular	2.36%
Direct	1.00%

Including additional expenses and goods and service tax on management fees.

Other Parameters

Standard Deviation	14.85%
Sharpe Ratio	0.42
Beta	0.94
Portfolio Turnover	0.29
Treynor Ratio	0.07

Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.86% (FBIL Overnight MIBOR as on 30 June 2024) for calculating Sharpe Ratio

Application Amount for fresh subscription

₹ 1,000 (plus in multiples of ₹ 1)

Min. Addl. Investment

₹ 1,000 (plus in multiples of ₹ 1)

PORTFOLIO

Issuer	% to Net Assets
Pharmaceuticals & Biotechnology	76.02%
Sun Pharmaceutical Industries Limited	14.63%
Cipla Limited	8.72%
Torrent Pharmaceuticals Limited	7.62%
Aurobindo Pharma Limited	5.78%
Zydus Lifesciences Limited	4.66%
Ajanta Pharmaceuticals Limited	4.15%
Gland Pharma Limited	3.99%
Lupin Limited	3.73%
Alkem Laboratories Limited	3.48%
Abbott India Limited	3.10%
J.B. Chemicals & Pharmaceuticals Limited	3.02%
ALEMBIC PHARMACEUTICALS LIMITED	2.95%
Dr. Reddys Laboratories Limited	2.85%
Strides Pharma Science Limited	2.70%
Sanofi India Limited	2.09%

Issuer	% to Net Assets
Mankind Pharma Ltd	1.34%
Sanofi India Limited	1.21%
Healthcare Services	15.97%
Apollo Hospitals Enterprise Limited	6.41%
Fortis Healthcare Limited	4.85%
Jupiter Life Line Hospitals Ltd	2.39%
Vijaya Diagnostic Centre Limited	2.32%
Insurance	3.02%
Star Health & Allied Insurance Limited	1.91%
Medi Assist Healthcare Services Ltd	1.11%
Chemicals & Petrochemicals	1.04%
Vinati Organics Limited	1.04%
Retailing	0.54%
Medplus Health Services Limited	0.54%
Cash & Current Assets	3.41%
Total Net Assets	100.00%

Investment Performance

NAV as on June 28, 2024: ₹ 27.0700

Inception - July 11, 2019	Since Inception	5 Years	3 Years	1 Year
Aditya Birla Sun Life Pharma & Healthcare Fund	22.17%	NA	13.03%	42.31%
Value of Std Investment of ₹ 10,000	27070	NA	14437	14217
Benchmark - BSE Healthcare TRI	24.85%	NA	13.95%	44.83%
Value of Std Investment of ₹ 10,000	30154	NA	14790	14469
Additional Benchmark - Nifty 50 TRI	17.36%	NA	16.55%	26.74%
Value of Std Investment of ₹ 10,000	22163	NA	15826	12666

Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 8. Total Schemes managed by Mr. Dhaval Joshi is 51.

Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.

SIP Performance - Regular Plan - Growth (assuming SIP of ₹ 10000 per month)

Particulars	Since Inception	5 years	3 years	1 Year
Total Amount Invested (₹)	600000	NA	360000	120000
Market Value of amount Invested	1022230	NA	507116	141665
Scheme Returns (CAGR)	21.52%	NA	23.68%	35.66%
BSE Healthcare TRI# (CAGR)	24.23%	NA	25.99%	42.07%
Nifty 50 TRI## (CAGR)	20.46%	NA	19.80%	31.54%

Past Performance may or may not be sustained in future. The fund's inception date is July 11, 2019, and the initial SIP installment is considered to have been made on that date. Subsequent installments occur on the first day of every following month.

Scheme Benchmark, ## Additional Benchmark

For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return). Where Benchmark returns are not available, they have not been shown. Past performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration.

NAV of Plans / Options (₹)


	Regular Plan	Direct Plan
Growth	27.0700	29.3000
IDCW#:	20.4400	21.7900

#Income Distribution cum capital withdrawal

Product Labeling Disclosures

Aditya Birla Sun Life Pharma & Healthcare Fund
(An Open Ended equity scheme investing in Pharma and Healthcare Services Sector)

- Long term capital growth
- Investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India



*Investors should consult their financial advisors if in doubt whether the product is suitable for them.